Blood Res.  2019 Mar;54(1):77-79. 10.5045/br.2019.54.1.77.

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib

• Yi JH
• Kim HR

• KMID: 2451060
• DOI: http://doi.org/10.5045/br.2019.54.1.77

Abstract

No abstract available.

MeSH Terms

Dasatinib*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Primary Myelofibrosis*
Dasatinib

Figure

• 

  Fig. 1 Bone marrow biopsy specimens at the time of diagnosis (hematoxylin and eosin stain, ×400). Atypical megakaryocytes showing cloud-like nuclei with a high nucleusto-cytoplasm ratio (A). Dense clusters of megakaryocytes (B).

• 

  Fig. 2 Clinicolaboratory course of the patient. a)Number of Ph+ cells/number of analyzed cells by chromosome analysis; b)Number of Ph+ cells/number of analyzed cells by fluorescence in situ hybridization analysis. Ph+, Philadelphia chromosome-positive.

Reference

1. Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC Press;2017.

2. Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007; 109:4106–4107.

3. Krämer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007; 8:658–660.

4. Bornhäuser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007; 21:1824–1826.

5. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007; 21:1103–1104.

6. Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008; 22:1454–1455.

7. Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011; 117:e198–e206.

8. Pieri L, Spolverini A, Scappini B, et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood. 2011; 118:3445–3446.

9. Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J. 2015; 5:e351.

10. Iurlo A, Gianelli U, Rapezzi D, et al. Imatinib and ruxolitinib association: first experience in two patients. Haematologica. 2014; 99:e76–e77.